FDA
-
-
-
-
-
-
-
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
-
-
-
-
-
-
-
Genprex abstract selected for 2026 ASCO meeting on lung cancer therapy
-
-
-
-
-
-
-
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
-
-
-
-
-
-
-
Genprex reports preclinical data for diabetes gene therapy GPX-002
-
-
-
-
-
-
-
GENPREX receives European patent intent for cancer gene therapy combination
-
-
-
-
-
-
-
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Genprex issues stockholder letter with 2025 corporate update
-
328,333 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

